Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes

E-ISSN： 1875-5607|17|11|947-958

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.17, Iss.11, 2017-06, pp. : 947-958

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes

By Quattrin Teresa

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2597-2604

Informa Healthcare

Access to resources Recommend Favorite

GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges

Current Drug Targets, Vol. 17, Iss. 11, 2016-07 ,pp. : 1292-1300

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes

Current Drug Targets, Vol. 9, Iss. 10, 2008-10 ,pp. : 911-920

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging treatments for the prevention of type 1 diabetes

By Raskin Philip Mohan Alok

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 225-236

Informa Healthcare

Access to resources Recommend Favorite

SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 291-298

Bentham Science Publishers

Access to resources Recommend Favorite